Publications by authors named "L K Law"
Background: Structured training in regional anaesthesia includes pretraining on simulation-based educational platforms to establish a safe and controlled learning environment before learners are provided clinical exposure in an apprenticeship model. This scoping review was designed to appraise the educational outcomes of current simulation-based educational modalities in regional anaesthesia.
Methods: This review conformed to PRISMA-ScR guidelines.
Article Synopsis
- Rhesus macaques vaccinated with RhCMV/SIV show about 59% protection against SIVmac239M exposure, but the mechanism behind this protection is still unclear.
- Researchers explored how the gut microbiome of the macaques influences the effectiveness of the vaccine, analyzing rectal swabs for microbial profiles before and after SIV exposure.
- They discovered a common gut microbial signature associated with vaccine protection across different vaccination groups, indicating that gut microbiota play a significant role in the immune response to the RhCMV/SIV vaccine.
Background: Food insecurity prevails in people at all phases of their life course and causes remarkable health, social, and financial repercussions. In Sarawak state, Malaysia, information regarding household food insecurity is limited.
Objectives: The objective of this study was to examine the prevalence of household food insecurity, together with its predictors and coping strategies among the Sarawak indigenous communities.
Dimethyl sulfoxide (DMSO) has wide biomedical applications such as cryoprotectant and hydrophobic drug carrier. Here, we report for the first time that DMSO can generate a distinctive chemical exchange saturation transfer (CEST) signal at around -2 ppm. Structural analogs of DMSO, including aprotic and protic solvents, also demonstrated CEST signals from -1.
View Article and Find Full Text PDFBackground: Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is one of the first line treatments for diffuse large B-cell lymphoma (DLBCL). Rituximab comprises most of the treatment cost for this regimen; therefore, biosimilars, such as rituximab-abbs are crucial to provide affordable care. Although rituximab-abbs was studied primarily in follicular lymphoma, the Food and Drug Administration (FDA) approved this drug for all indications of the reference product on the basis of extrapolation.
View Article and Find Full Text PDF